Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study

Míreanna Comhchosúla

• Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study
  le: Harnam Neesha, et al.
  Foilsithe: (2008-10-01)
• Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
  le: Menter, Alan, et al.
  Foilsithe: (2016)
• Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
  le: Moore, Angela Y, et al.
  Foilsithe: (2010)
• A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
  le: Campa, Molly, et al.
  Foilsithe: (2015)
• Visual Loss Induced by Adalimumab Used for Plaque Psoriasis
  le: Saffra, Norman, et al.
  Foilsithe: (2017)